Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» FDA staff highlight heart risk with Novo insulin
FDA staff highlight heart risk with Novo insulin
FDA staff highlight heart risk with Novo insulin
Submitted by
admin
on November 6, 2012 - 10:12am
Source:
Reuters
News Tags:
Novo Nordisk
FDA
insulin
degludec
Headline:
FDA staff highlight heart risk with Novo insulin
Do Not Allow Advertisers to Use My Personal information
